A research study co-authored by Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders will be ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...

The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

John "Chip" Scarlett, who as chairman, president and CEO repositioned Geron Corp. and guided the company to its first drug ...

Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...